Login
Home
Charts
Search
Watchlist
Products

Meghmani Organics Ltd

MOL·NSE
61.91+0.75%Wed, 23 Sept '26 12:25

Meghmani Organics Ltd

MOL
NSE
61.91
+0.75%
|Wed, 23 Sept '26 12:25
SOICxStockScans Reports
6M
Price
Charts
Documents

Quick Ratios

Edit Ratios
Mkt Cap
Market Capitalization
1,578Cr
Close
Close Price
62.04
Industry
Industry
Pesticides/Agrochemicals
PE
Price To Earnings
24.52
PS
Price To Sales
0.75
Revenue
Revenue
2,103Cr
Rev Gr TTM
Revenue Growth TTM
-7.73%
PAT Gr TTM
PAT Growth TTM
240.98%

Quarterly Results

Consolidated
Standalone
Numbers
Percentage
QuarterSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue
RevenueCr
379352410414544569553614577509474543
Growth YoY
Revenue Growth YoY%
-41.4-36.0-28.6-2.843.661.635.048.36.1-10.5-14.3-11.5
Expenses
ExpensesCr
371360408408513528488547525471455445
Operating Profit
Operating ProfitCr
8-8263141656752382098
OPM
OPM%
2.0-2.20.51.45.67.211.810.99.07.44.218.0
Other Income
Other IncomeCr
121099129141728153712
Interest Expense
Interest ExpenseCr
13272112613192924182013
Depreciation
DepreciationCr
232323232530293030302930
PBT
PBTCr
-16-48-14-19-973124265767
Tax
TaxCr
0-104-30121112158-119
PAT
PATCr
-15-38-18-17-9-4201312-4848
Growth YoY
PAT Growth YoY%
-123.2-557.8-133.251.439.688.5210.4175.7224.619.6-59.5280.1
NPM
NPM%
-4.0-10.9-4.4-4.0-1.7-0.83.62.12.0-0.71.78.9
EPS
EPS
-0.6-1.5-0.7-0.7-0.4-0.20.80.50.5-0.10.31.9
QuarterSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue
RevenueCr
379352410414544569553614577509474543
Growth YoY
Revenue Growth YoY%
-41.4-36.0-28.6-2.843.661.635.048.36.1-10.5-14.3-11.5
Expenses
ExpensesCr
371360408408513528488547525471455445
Operating Profit
Operating ProfitCr
8-8263141656752382098
OPM
OPM%
2.0-2.20.51.45.67.211.810.99.07.44.218.0
Other Income
Other IncomeCr
121099129141728153712
Interest Expense
Interest ExpenseCr
13272112613192924182013
Depreciation
DepreciationCr
232323232530293030302930
PBT
PBTCr
-16-48-14-19-973124265767
Tax
TaxCr
0-104-30121112158-119
PAT
PATCr
-15-38-18-17-9-4201312-4848
Growth YoY
PAT Growth YoY%
-123.2-557.8-133.251.439.688.5210.4175.7224.619.6-59.5280.1
NPM
NPM%
-4.0-10.9-4.4-4.0-1.7-0.83.62.12.0-0.71.78.9
EPS
EPS
-0.6-1.5-0.7-0.7-0.4-0.20.80.50.5-0.10.31.9

Profit & Loss

Consolidated
Standalone
Numbers
Percentage
Financial YearMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Revenue
RevenueCr
1,8032,0887001,6372,4982,5531,5662,0802,1742,103
Growth
Revenue Growth%
15.8-66.5134.052.72.2-38.632.84.5-7.7
Expenses
ExpensesCr
1,3721,5435951,3542,1202,2121,5871,9371,9981,896
Operating Profit
Operating ProfitCr
431544104282379341-20143176207
OPM
OPM%
23.926.114.917.315.213.4-1.36.98.19.9
Other Income
Other IncomeCr
29171313110211538449692
Interest Expense
Interest ExpenseCr
4056181196646699275
Depreciation
DepreciationCr
95972251637792108119119
PBT
PBTCr
326409194252409313-121962105
Tax
TaxCr
88113456510475-15203340
PAT
PATCr
238295150186304238-106-112964
Growth
PAT Growth%
24.1-49.424.763.3-21.9-144.690.0371.1241.0
NPM
NPM%
13.214.221.411.412.29.3-6.8-0.51.33.0
EPS
EPS
6.79.95.97.312.09.3-4.2-0.41.12.5
Financial YearMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Revenue
RevenueCr
1,8032,0887001,6372,4982,5531,5662,0802,1742,103
Growth
Revenue Growth%
15.8-66.5134.052.72.2-38.632.84.5-7.7
Expenses
ExpensesCr
1,3721,5435951,3542,1202,2121,5871,9371,9981,896
Operating Profit
Operating ProfitCr
431544104282379341-20143176207
OPM
OPM%
23.926.114.917.315.213.4-1.36.98.19.9
Other Income
Other IncomeCr
29171313110211538449692
Interest Expense
Interest ExpenseCr
4056181196646699275
Depreciation
DepreciationCr
95972251637792108119119
PBT
PBTCr
326409194252409313-121962105
Tax
TaxCr
88113456510475-15203340
PAT
PATCr
238295150186304238-106-112964
Growth
PAT Growth%
24.1-49.424.763.3-21.9-144.690.0371.1241.0
NPM
NPM%
13.214.221.411.412.29.3-6.8-0.51.33.0
EPS
EPS
6.79.95.97.312.09.3-4.2-0.41.12.5

Balance Sheet

Consolidated
Standalone
Numbers
Percentage
Financial YearMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
Equity CapitalCr
252525252525252525
Reserves
ReservesCr
8459789611,1481,4411,6441,5021,4901,519
Current Liabilities
Current LiabilitiesCr
4527075526141,0351,0301,0561,2041,226
Non Current Liabilities
Non Current LiabilitiesCr
274516119187297499456367249
Total Liabilities
Total LiabilitiesCr
1,8182,3771,6571,9742,7983,1983,0403,0853,021
Current Assets
Current AssetsCr
8391,0718539951,4371,4661,2131,3501,315
Non Current Assets
Non Current AssetsCr
9791,3058049791,3611,7331,8271,7351,705
Total Assets
Total AssetsCr
1,8182,3771,6571,9742,7983,1983,0403,0853,021
Financial YearMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
Equity CapitalCr
252525252525252525
Reserves
ReservesCr
8459789611,1481,4411,6441,5021,4901,519
Current Liabilities
Current LiabilitiesCr
4527075526141,0351,0301,0561,2041,226
Non Current Liabilities
Non Current LiabilitiesCr
274516119187297499456367249
Total Liabilities
Total LiabilitiesCr
1,8182,3771,6571,9742,7983,1983,0403,0853,021
Current Assets
Current AssetsCr
8391,0718539951,4371,4661,2131,3501,315
Non Current Assets
Non Current AssetsCr
9791,3058049791,3611,7331,8271,7351,705
Total Assets
Total AssetsCr
1,8182,3771,6571,9742,7983,1983,0403,0853,021

Cash Flow

Consolidated
Standalone
Financial YearMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow
Operating Cash FlowCr
405375223336520425066222
Investing Cash Flow
Investing Cash FlowCr
-275-291-3-307-133-418-17831-38
Financing Cash Flow
Financing Cash FlowCr
-12845-26-1458234-85-91-190
Net Cash Flow
Net Cash FlowCr
2129-812-1021-146-7
Free Cash Flow
Free Cash FlowCr
163-1-49124-177-259-14-20178
CFO To PAT
CFO To PAT%
170.2126.914.7178.821.386.0-235.5-624.7771.6
CFO To EBITDA
CFO To EBITDA%
93.968.821.1118.017.160.0-1,231.546.4125.7
Financial YearMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow
Operating Cash FlowCr
405375223336520425066222
Investing Cash Flow
Investing Cash FlowCr
-275-291-3-307-133-418-17831-38
Financing Cash Flow
Financing Cash FlowCr
-12845-26-1458234-85-91-190
Net Cash Flow
Net Cash FlowCr
2129-812-1021-146-7
Free Cash Flow
Free Cash FlowCr
163-1-49124-177-259-14-20178
CFO To PAT
CFO To PAT%
170.2126.914.7178.821.386.0-235.5-624.7771.6
CFO To EBITDA
CFO To EBITDA%
93.968.821.1118.017.160.0-1,231.546.4125.7

Ratios

Consolidated
Standalone
Financial YearMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Current
Valuation Ratios
Valuation Ratios
Market Cap
Market CapitalizationCr
2,6511,9742,0171,5609321,578
Price To Earnings
Price To Earnings
8.78.332.424.5
Price To Sales
Price To Sales
1.10.81.30.80.40.8
Price To Book
Price To Book
1.81.21.31.00.61.0
EV To EBITDA
EV To EBITDA
8.38.1-139.716.59.311.0
Profitability Ratios
Profitability Ratios
GPM
GPM%
37.340.129.032.528.626.816.022.423.123.1
OPM
OPM%
23.926.114.917.315.213.4-1.36.98.19.9
NPM
NPM%
13.214.221.411.412.29.3-6.8-0.51.33.0
ROCE
ROCE%
31.228.117.618.321.315.2-3.23.46.86.8
ROE
ROE%
27.329.415.215.920.814.2-6.9-0.71.91.9
ROA
ROA%
13.112.49.09.410.97.4-3.5-0.30.90.9
Operational Ratios
Operational Ratios
Solvency Ratios
Solvency Ratios
Liquidity Ratios
Liquidity Ratios
Financial YearMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Current
Valuation Ratios
Valuation Ratios
Market Cap
Market CapitalizationCr
2,6511,9742,0171,5609321,578
Price To Earnings
Price To Earnings
8.78.332.424.5
Price To Sales
Price To Sales
1.10.81.30.80.40.8
Price To Book
Price To Book
1.81.21.31.00.61.0
EV To EBITDA
EV To EBITDA
8.38.1-139.716.59.311.0
Profitability Ratios
Profitability Ratios
GPM
GPM%
37.340.129.032.528.626.816.022.423.123.1
OPM
OPM%
23.926.114.917.315.213.4-1.36.98.19.9
NPM
NPM%
13.214.221.411.412.29.3-6.8-0.51.33.0
ROCE
ROCE%
31.228.117.618.321.315.2-3.23.46.86.8
ROE
ROE%
27.329.415.215.920.814.2-6.9-0.71.91.9
ROA
ROA%
13.112.49.09.410.97.4-3.5-0.30.90.9
Operational Ratios
Operational Ratios
Solvency Ratios
Solvency Ratios
Liquidity Ratios
Liquidity Ratios
Meghmani Organics started in 1986 with a single plant making green pigment, and over nearly four decades it has grown into a diversified chemical manufacturer that now reaches customers in more than 75 countries. The company’s recurring approach is backward integration - making its own key raw materials in-house rather than buying them from others, especially from China - which gives it control over costs and supply. Today, the second generation of the founding family runs a business built on agrochemicals, pigments, crop nutrition, and titanium dioxide, all manufactured across nine integrated plants in Gujarat’s chemical belt. # Business segments Four engines at different stages - a global agrochemical export powerhouse, a pigment operation that is the world’s largest of its kind, a nano-fertiliser platform riding India’s import-substitution wave, and a titanium dioxide plant paused mid-flight - each built on the same backward-integration playbook. ## 1. Crop Protection: the engine that drives the company **A vertically integrated pesticide manufacturer that makes everything from raw intermediates to finished farmer-ready formulations, with nearly nine out of every ten rupees of revenue coming from exports.** - **Makes the whole chain, not just one link** - the segment manufactures intermediates, technical-grade pesticides (the concentrated active ingredient), and final formulations under its own brands like Megacyper and Megastar, so it captures value at every stage rather than selling raw material to someone else who then makes the finished product. - **Backward-integrated into key building blocks** - it produces cypermethric acid chloride, meta phenoxy benzaldehyde, and meta phenoxy benzyl alcohol in-house, which reduces dependence on imported intermediates and insulates the business from supply shocks. - **One of very few makers of complex molecules** - at its Multi-Purpose Plant in Dahej, it manufactures high-value insecticides like Flubendamide and Spiromesifen where it is either the only Indian producer after multinational corporations or the second, giving it pricing power that commodity players lack. - **A registration moat that takes years to replicate** - the segment holds 893 product registrations split between export markets and India’s Central Insecticides Board, and runs its own GLP-accredited lab with over 35 scientists to generate the data needed for new registrations faster and cheaper. - **Distribution that reaches the farmer and the multinational buyer** - domestically it reaches roughly 10 million Indian farmers through 3,500-plus distributors across 19 states, while on the export side it serves over 400 marquee customers with 45% of demand coming from the US and Brazil. ## 2. Pigments: the world’s largest phthalocyanine player **The biggest manufacturer globally of copper-phthalocyanine-based blue and green pigments, with a client base so sticky that 90% of business comes from repeat customers.** - **The original business, now a global number one** - what began as a single Pigment Green 7 plant in 1986 has become the largest producer of phthalocyanine pigments worldwide, with an 8% global market share and a position among the top three by capacity. - **Three plants, one dedicated to exports** - manufacturing is spread across Vatva, Panoli, and a Dahej SEZ unit that ships exclusively to international markets, serving ink, paint, plastic, and polymer industries in more than 75 countries. - **Customisation locks customers in** - the segment retains nine out of ten clients year after year because it tailors products to their specifications and maintains consistent quality and compliance standards, making switching costly for buyers. - **A US subsidiary shortens the supply chain** - Meghmani Organics USA INC acts as a local distribution arm for international pigment demand, handling logistics and customer relationships on the ground. ## 3. Crop Nutrition: a nano-fertiliser bet on India’s urea problem **India imports billions of dollars of conventional urea every year; this segment makes a liquid nano-alternative that is cheaper, more effective, and sold through the same dealer network as the pesticides business.** - **First private player to license IFFCO’s nano technology** - through a strategic agreement with the farmer cooperative giant IFFCO, MOL became the first private company to manufacture Nano Urea using a domestically developed patented process, giving it a head start over potential competitors. - **One bottle replaces one bag, at a lower cost** - a 500 ml bottle of Nano Urea contains nitrogen equivalent to a full bag of conventional urea but is over 80% effective versus 30-40% for granular urea, and at ₹225 per bottle it is 15% cheaper for the farmer. - **Rides the same distribution rails as Crop Protection** - the segment is an allied business that uses the existing marketing and channel network of the agrochemical division, so it scales without building a separate sales force from scratch. - **Expanding the product shelf rapidly** - beyond Nano Urea, the portfolio now includes bio-fertilisers, organic fertilisers, micronutrients, and biostimulants, and in 2026 it received government approval to add Nano DAP, Nano NPK, and Nano Zinc using the same Sanand plant infrastructure with no extra capital spend. - **Export trials are already running** - field trials for Nano Urea are underway in 35-40 countries across Latin America, Africa, and Asia, with the company interacting with export market customers in these regions, opening a path beyond India’s borders. ## 4. Titanium Dioxide: a paused white-pigment play **An import-substitution bet on the white pigment that makes paint bright, built by acquiring a distressed plant - currently suspended because raw-material costs and Chinese dumping made it uneconomic.** - **Bought, not built from the ground up** - MOL entered the TiO₂ business by acquiring Kilburn Chemicals through an NCLT-approved resolution plan in 2021 for ₹131.76 crore, getting a ready 16,500 MTPA plant at Dahej rather than spending years on construction. - **India imports most of what it consumes** - the country’s TiO₂ market is roughly 4,85,000 tonnes a year and growing at double digits, but about 79% is imported, with China supplying 62% of those imports - a gap the plant was designed to fill. - **A captive power plant to tackle the biggest cost** - a 12 MW co-generation unit was commissioned at the facility to bring down energy expenses, which are a major component of TiO₂ manufacturing via the sulphate process. - **Operations halted, but the anti-dumping tide may be turning** - the plant was suspended because high sulphuric acid costs and weak prices after an anti-dumping duty on Chinese imports was withdrawn made it commercially unviable; a fresh anti-dumping duty became effective in May 2025, and the trade authority is reviewing the matter again. # Group structure and partners **A single listed parent with two wholly owned operating subsidiaries that are being merged back in, plus a growing international distribution footprint.** - **International subsidiaries for on-the-ground access** - a US subsidiary handles pigment distribution, while a newly incorporated Brazilian subsidiary will manage commercialisation and distribution of agrochemicals in one of the world’s largest crop-protection markets, worth close to USD 15 billion. - **Strategic partnerships fill technology gaps** - the IFFCO agreement provided the nano-urea manufacturing technology, and a renewable-energy supply agreement with Pro-Zeal Green Power Fifteen Private Limited gives MOL captive access to 3.30 MW of wind-solar hybrid power.

Documents — Meghmani Organics Ltd

  • Q1 FY2027 Earnings Call Transcript (Jun 2026, PDF): https://www.stockscans.in/document/iw5yfra5tyiqv113axpxokrk.pdf
  • Q4 FY2026 Earnings Call Transcript (Mar 2026, PDF): https://www.stockscans.in/document/3ly7y60sp2knfcut8v450myf.pdf
  • Q3 FY2026 Earnings Call Transcript (Dec 2025, PDF): https://www.stockscans.in/document/0ruy0n3s1w84or7uihufcc4n.pdf
  • Q2 FY2026 Earnings Call Transcript (Sep 2025, PDF): https://www.stockscans.in/document/eliolmsp13h347jmpehcce0j.pdf
  • Q1 FY2026 Earnings Call Transcript (Jun 2025, PDF): https://www.stockscans.in/document/fdufnbi3lib0fisbnbk2aujm.pdf
  • Q4 FY2025 Earnings Call Transcript (Mar 2025, PDF): https://www.stockscans.in/document/hhvtntzyw96rqt29oqq5oi6i.pdf
  • Q3 FY2025 Earnings Call Transcript (Dec 2024, PDF): https://www.stockscans.in/document/p4bezt9d5hi0cgcw9pa06o2a.pdf
  • Q2 FY2025 Earnings Call Transcript (Sep 2024, PDF): https://www.stockscans.in/document/qadgka8nzoa1vt9lk02s6y8y.pdf
  • Q1 FY2027 Quarterly Result (Jun 2026, PDF): https://www.stockscans.in/document/0jsie8ih95bujhxyd2cjv6n1.pdf
  • Q4 FY2026 Quarterly Result (Mar 2026, PDF): https://www.stockscans.in/document/40qhw3mu1s717t2y7skqjimh.pdf
  • Q3 FY2026 Quarterly Result (Dec 2025, PDF): https://www.stockscans.in/document/jjl8j7fb8gylgx288r3ww6nu.pdf
  • Q2 FY2026 Quarterly Result (Sep 2025, PDF): https://www.stockscans.in/document/xhd39a00vz20p9lzcjzokfnx.pdf
  • Q1 FY2026 Quarterly Result (Jun 2025, PDF): https://www.stockscans.in/document/hpxaw2ivfm7wv8aghgg4cv6p.pdf
  • Q4 FY2025 Quarterly Result (Mar 2025, PDF): https://www.stockscans.in/document/351nsr5jxch2pjp9rki7vv60.pdf
  • Q3 FY2025 Quarterly Result (Dec 2024, PDF): https://www.stockscans.in/document/yex985ypj2ok3vzj8g38w9ul.pdf
  • Q2 FY2025 Quarterly Result (Sep 2024, PDF): https://www.stockscans.in/document/kqme3l14ltknlhlvxx2nezir.pdf
  • Q1 FY2027 Investor Presentation (Jun 2026, PDF): https://www.stockscans.in/document/hxsexouz7q0cn0nvy3jm1xrw.pdf
  • Q4 FY2026 Investor Presentation (Mar 2026, PDF): https://www.stockscans.in/document/dewwfioe94lm36jzf479lyd0.pdf
  • Q3 FY2026 Investor Presentation (Dec 2025, PDF): https://www.stockscans.in/document/whqpr9o8h5p6qqn1c4lsyfu5.pdf
  • Q2 FY2026 Investor Presentation (Sep 2025, PDF): https://www.stockscans.in/document/wih8w3p49l34ttvd4wuclztg.pdf
  • Q1 FY2026 Investor Presentation (Jun 2025, PDF): https://www.stockscans.in/document/npd5i9tzcqn3kbyhy858qu7a.pdf
  • Q4 FY2025 Investor Presentation (Mar 2025, PDF): https://www.stockscans.in/document/shayu17e09b3hfalt5wuy6w3.pdf
  • Q3 FY2025 Investor Presentation (Dec 2024, PDF): https://www.stockscans.in/document/u0j642vyiri5o9kafhry3dnr.pdf
  • Q2 FY2025 Investor Presentation (Sep 2024, PDF): https://www.stockscans.in/document/t2an0v0vs62jv91ysj5yvc3y.pdf
  • FY2026 Annual Report (PDF): https://www.stockscans.in/document/sxiti4e3lz45pgxwigmgyldb.pdf
  • FY2025 Annual Report (PDF): https://www.stockscans.in/document/84iz54vzquq984v5vp43uv1z.pdf
  • FY2024 Annual Report (PDF): https://www.stockscans.in/document/xnpf16eyzcvnpp1b1eb8ipha.pdf
  • FY2023 Annual Report (PDF): https://www.stockscans.in/document/ejp6q5om7oaj0b7ligysqouj.pdf
  • FY2022 Annual Report (PDF): https://www.stockscans.in/document/y7alqetrl6ai2s78wo4oenev.pdf
  • FY2021 Annual Report (PDF): https://www.stockscans.in/document/jg3wbqvbp8eutkxdp58yo314.pdf

Concall Transcript Summaries — Meghmani Organics Ltd

  • Q1 FY2027 Concall Transcript Summary (Jun 2026): https://www.stockscans.in/company/NSE%3AMOL/transcript-notes/202606/iw5yfra5tyiqv113axpxokrk.pdf
  • Q4 FY2026 Concall Transcript Summary (Mar 2026): https://www.stockscans.in/company/NSE%3AMOL/transcript-notes/202603/3ly7y60sp2knfcut8v450myf.pdf
  • Q3 FY2026 Concall Transcript Summary (Dec 2025): https://www.stockscans.in/company/NSE%3AMOL/transcript-notes/202512/0ruy0n3s1w84or7uihufcc4n.pdf
  • Q2 FY2026 Concall Transcript Summary (Sep 2025): https://www.stockscans.in/company/NSE%3AMOL/transcript-notes/202509/eliolmsp13h347jmpehcce0j.pdf
  • Q1 FY2026 Concall Transcript Summary (Jun 2025): https://www.stockscans.in/company/NSE%3AMOL/transcript-notes/202506/fdufnbi3lib0fisbnbk2aujm.pdf
  • Q4 FY2025 Concall Transcript Summary (Mar 2025): https://www.stockscans.in/company/NSE%3AMOL/transcript-notes/202503/hhvtntzyw96rqt29oqq5oi6i.pdf
  • Q3 FY2025 Concall Transcript Summary (Dec 2024): https://www.stockscans.in/company/NSE%3AMOL/transcript-notes/202412/p4bezt9d5hi0cgcw9pa06o2a.pdf
  • Q2 FY2025 Concall Transcript Summary (Sep 2024): https://www.stockscans.in/company/NSE%3AMOL/transcript-notes/202409/qadgka8nzoa1vt9lk02s6y8y.pdf